The State of Market Access in 2024


The Ultimate Guide to Tracking Performance in Market Access


The Ultimate Guide to Tracking Performance in Market Access


Access Hub™ by Access Infinity Wins Bronze Stevie® Award in 2023 International Business Awards®

Category-defining solution recognised for Technical Innovation of the Year

LONDON, UK — 14th August, 2023, Access Infinity is delighted to announce that it’s Access Hub™ solution was named the winner of a Bronze Stevie® Award in the Technical Innovation of the Year category in The 20th Annual International Business Awards®. 

The International Business Awards are the world’s premier business awards program. All individuals and organisations worldwide – public and private, for-profit and non-profit, large and small – are eligible to submit nominations. The 2023 IBAs received entries from organisations in 61 nations and territories. 

More than 3,700 nominations from organisations of all sizes and in virtually every industry were submitted this year for consideration in a wide range of categories, including Company of the Year, Marketing Campaign of the Year, Best New Product or Service of the Year, Startup of the Year, Corporate Social Responsibility Program of the Year, and Executive of the Year, among others. This year’s competition also featured several new categories to recognise organisations and individuals’ achievements in sustainability initiatives.

Access Infinity’s Access Hub solution won in the Technical Innovation of the Year category for organisations with up to 100 employees. Access Hub is an innovative SaaS solution designed exclusively for market access teams. Developed following extensive user research, the solution revolutionises global drug launches by empowering teams to make informed decisions, learn from past experiences, benchmark against competition, and showcase the success of their brands. 

Comments from the judging panel included: 

Good example of a solution business actually needs, with a well implemented launch campaign. Access Hub helps its customers to increase productivity and uniform reporting across brands.”

This is an excellent entry, showcasing outstanding work by Access Hub.”

You have an impressive product that helps pharma companies to launch products globally and track real time status supported by digitisation…”

"Access Hub is a category-defining product that has received a very positive response from the market access community since its launch last year. I’d like to congratulate and thank the team involved in the development and launch of this innovative solution. We’ve continued to put customer needs at the heart of all our products, and this latest award win is a testament to that."
Keshav Nagaraja
Managing Director, Access Infinity Digital
"Nominations to the IBAs get better every year, and this year’s class of Stevie winners is the most impressive yet. The winners have demonstrated that their organizations have set and achieved lofty goals.  We congratulate them on their recognized achievements and look forward to celebrating them on stage in Rome on 13 October.”
Maggie Miller
Stevie Awards President

Stevie Award winners were determined by the average scores of more than 230 executives worldwide who participated in the judging process in June and July.

Winners will be celebrated during a gala banquet at the Cavalieri Waldorf Astoria Hotel, in Rome, Italy on Friday, 13 October.

Details about The International Business Awards and the lists of Stevie Award winners are available at www.StevieAwards.com/IBA.

About Access Infinity

Founded in 2014, Access Infinity exists to help pharma companies confront their challenges head-on. The company began as a consulting firm to guide pharma businesses in developing and implementing effective market access and pricing strategies. It has since introduced market-redefining digital tools, NURO, Access Hub and Evidence Library to help market access teams work smarter, faster, and more efficiently with valuable insights at their fingertips.

With offices in London, Hyderabad, New York, and Manchester, Access Infinity is experiencing rapid growth as it continues to transform and simplify market access for pharmaceutical organizations globally. Clients include GSK, BMS, Astra Zeneca, Johnson & Johnson, Pfizer, and Amgen.

About the Stevie Awards

Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honouring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at www.StevieAwards.com.

For more information, press only:
Tel: +44 (0)207 078 7643

Learn the true value of Market Access Performance Tracking in our new guide

Download 'The ultimate guide to tracking performance in market access'

The Access Infinity team has just launched a new guide. The ultimate guide to tracking performance in market access offers key insights into the value-led strategies for launching new pharmaceutical products.

Authored by Access Infinity Founder Ahmed Edathodu, the guide takes market access professionals through the KPIs that help them to achieve the best price and broadest access in the shortest possible time. It also draws on testimonials from real customers, including Astellas and Pfizer.

Hear from the faces behind Access Infinity 

Access Infinity’s game-changing learnings, taken from years of working with top-tier pharma companies and interviews with access leaders, paint a clearer picture of market access performance tracking today. We hear from Founder Ahmed Edathodu, as well as Product Owner Thomas Gilboy.

What the guide will cover

The guide will address some of the most pertinent topics in market access performance tracking, including:

  • The state of market access performance today
  • Why measure market access performance
  • Why become a market access performance champion
  • How to measure market access performance
  • Who’s championing market access performance in industry
  • What to do next.

Why measure market access performance

While measuring market access has been on the agenda to some degree, understanding performance is becoming a priority at board and leadership level. So how can market access teams do it better and communicate their success?

Historically, while teams have relied on legacy technology like Microsoft Excel, this does not provide a holistic overview. Our new guide showcases exactly why and how we should measure market access performance – benchmarking our performance against competitors, target dates, industry averages and more. From improving our institutional knowledge to bettering patient care, there has never been a more crucial time to measure market access performance.

Likewise, having a keen eye on both internal and external data gives us competitive advantage. This guide shows market access teams how to leverage information in the public domain, as well as internal figures for future strategic planning.

Download the guide today

The ultimate guide to tracking performance in market access is an essential for market access teams that want to demonstrate commercial success stories. It comes as just one of many free resources from Access Infinity, including an upcoming benchmark report and ‘Market Access Matters’ podcast. You can also find out more in our on-demand webinars.

Gain deeper insights and plan for a more profitable future. Read our free guide today. 

To get a copy of the full guide, complete the form below and we’ll be in touch by email.

Join us

Manager, Market Access

About the role:

Managers are responsible for organising and analysing our data sets to develop insights that can be transformed into client facing deliverables under the supervision of a Pricing & Market Access Lead. Managers need to be comfortable with large sets of data and ensure deliverables are always on time and meet the high standards expected by our clients.

To be successful, you will have:

  • An understanding of different healthcare settings and pricing and reimbursement of medicines in major EU markets, US and Japan.
  • Comfortable working with large volumes of technical pricing and market access data, performing analysis to generate insight and identifying anomalies.
  • Able to manipulate data in Excel and produce engaging Word and PowerPoint documents.
  • Any other knowledge of biopharma pricing, reimbursement, and commercialisation a plus.
  • Must have around 1-year relevant experience in global market access consulting.
  • Excellent IT skills e.g., Word, PowerPoint, Excel, and web-based applications.
  • Excellent time management and organizational skills. 

Your day-to-day responsibilities will be:

  • To work closely within a multidisciplinary team and the project lead, ensuring a consistently high quality of research and reporting.
  • Support all stages of platform/platform services project work for strategic and operational pricing, market access due diligence and price & revenue analytics.
  • Support the creation of client-ready reports, presentations, and other client deliverables within the platform space.
  • Conduct secondary research and work independently to assure correct and relevant information and analysis are provided.
  • Manages data collection, processing, quality assurance and client delivery.
  • Liaise with clients regarding data and technical queries and support services independently.
  • Performing qualitative (scientific, clinical, commercial) and quantitative analyses.
  • Organise and analyse data sets to develop insights that can be transformed into client facing deliverables.
  • Data and analytics-focused practice with large sets of data and ensure deliverables are always on time and meet the high standards expected by our clients.

About you: 

  • Undergraduate degree in a relevant scientific discipline plus graduate degree (Masters) in relevant discipline (including health economics, epidemiology, health services research, public health, or business management).
  • 4-5 years of experience working on pricing and reimbursement data for pharmaceutical products in Industry (pricing, forecasting, more general commercial strategy) or managed care/reimbursement policy consulting or related experience (strategy consulting to healthcare industry, market research) that supplements an advanced degree.
  • Demonstrated knowledge of pricing and reimbursement content, issues, and methodologies.
  • Demonstrated excellence in clarity and completeness in oral, written and presentation skills.
  • Demonstrated skills in communication.
  • Able to manage multiple tasks simultaneously.
  • An understanding of pharmaceutical pricing and reimbursement systems in target geography. 

Please email your CV and cover letter along to careers.india@accessinfinity.com with the role you are applying for as the subject.


World EPA Congress 2023: Our Takeaways

It was another standout World Evidence, Pricing and Access (EPA) Congress this March. More than 1,200 delegates attended to visit 100 exhibitors and watch 300 presentations at the RAI Congress Centre in Amsterdam.

This year’s resounding themes were focusing on the patient perspective, putting them at the heart of market access. These themes extended to the true definition of patient outcomes, and the need to look beyond initial patient care.

Nothing stands still in market access, and we were encouraged to “never stop exploring”. 

Key messages on the growth of the market access function

Echoing the sentiment of never standing still, we turn to the panel discussions. On Day 1, speakers from A.M. Pharma, GSK and Janssen discussed Exploring the use of access operating models.

Christoph Glaetzer, Chief Global Value and Access Officer at The Janssen Pharmaceutical Companies of Johnson & Johnson said: At its core, market access is not a function, it’s a strategy. And it’s because we need subject matter experts that it became a function.”

Within this, we are seeing an evolution of market access, with more light being shone on price function.

Making medicines available to patients

The event also highlighted some key statistics around medicine availability. Notable conclusions were the relatively high speed of access in Germany, compared to the concerningly slow pace in Romania.

There continue to be discrepancies across Europe. In Germany, only 8% of medicines are unavailable, whereas Spain suffers from 47% unavailability, and Lithuania 83%. We may see additional challenges as the UK turns to a US-like model for regulatory decisions.

In general, many low-middle-income countries have been overlooked when it comes to country registrations and P&R strategies. Our hope is that the new trends in access planning will improve access for all.

Feedback from the Access Infinity stand

Away from the panels, the whole Access Infinity team loved connecting with delegates on our stand. In particular, visitors showed a keen interest in:

  • The digitalisation of market access
  • Overall digital transformation in market access planning
  • How to use modern tech to streamline processes and make teams more efficient.
On the first day of the event, we were delighted to announce the availability of our NURO solution on the Microsoft Azure Marketplace, making it even easier for organisations to subscribe to our platform through their existing Microsoft Enterprise Agreement. Read the full story here.
Our teams also had some keen insights to share from the patient perspective. In particular, it’s essential to monitor the patient not only during their treatment, but afterwards. Patient-reported outcomes are ideal for measuring this, looking at real-world evidence as well as general outcomes.

Thought-provoking talks from our team

In addition to our stand, we took to the stage. Digital Solutions Product Owner Thomas Gilboy  on Day 1 and Founding Director Shri Mukku on Day 2. We delivered game-changing insights on the state of market access right now, plus actionable tips for analogue analysis.

The talks underscored the influence of market access and pricing functions on clinical and commercial operations. They also addressed the common mistakes made and how to avoid them – as guided by more than 10 years’ experience in the industry.

The future of access planning: key opportunities

Looking to the future, the conference wound down with an overview of emerging trends. These started with better access planning, focusing on affordability and inclusive business models. Proponents of this strategy include:

  • Sanofi’s non-profit impact brand
  • Pfizer’s accord for a healthier world.

With these influential brands at the helm, we should see these trends start to increase. Another brand setting a new trend is Novartis. The Novartis Access Model aims to increase access to on- and off-patent medicines for noncommunicable diseases in Africa, Latin America and Asia.

Best practices from world-leading brands

The Novartis name came up again as a leading example of tailored pricing strategies. Joining them were GSK and Pfizer, who have implemented strong access strategies among different income classifications.

These have given rise to new opportunities in product delivery and access planning. On top of equitable pricing strategies, we’ll also see more registrations and the use of non-exclusive voluntary licensing. In the future, this may lead to further scaling in access.

On the access planning front, there is now more focus on comprehensive plans for late-stage R&D products. The quality of these plans will be improved, no doubt bolstered by technology like Access Infinity.

Looking ahead to 2024

It’s hard to believe that after three days, 300 talks and 100 exhibitors, the World EPA Congress is over for another year. We’re excited to see these trends develop, taking a patient-first approach and making medicines accessible to all.

The World EPA Congress returns to Amsterdam between March 12 and 13, 2024.

We’re also heading out to ISPOR US and Europe events later this year, we look forward to seeing many of you soon! 

Missed the event and want to connect with us? Get in touch here. 


NURO from Access Infinity Now Available in the Microsoft Azure Marketplace

Microsoft Azure customers worldwide now gain access to NURO to take advantage of the scalability, reliability and agility of Azure to drive application development and shape business strategies.

LONDON, UK — March 21, 2023, Access Infinity, an award-winning market access consultancy and digital solutions firm, today announced the availability of NURO in the Microsoft Azure Marketplace, an online store providing applications and services for use on the Azure platform. Companies interested in subscribing to NURO can now do this easily through their existing Microsoft Enterprise Agreement.

NURO is a comprehensive analogue analysis and competitive insights platform that brings together HTA (health technology assessment), evidence, pipeline, pricing intelligence and other critical business insights all in one place. It allows the pharmaceutical industry’s global market access professionals to answer their key business questions in a highly robust manner, using a unique analogue analysis approach.

The SaaS offering is one of the three digital solutions offered by Access Infinity, a business which combines industry-leading consultancy services and technology to deliver market access and pricing strategy support.

"We’re delighted that NURO is now transacting in the Azure Marketplace. This represents a key milestone in broadening the reach of this powerful application. We believe NURO should be in the hands of all market access professionals, empowering them to achieve robust strategic decision-making supported by rapid analogue assessment and situational understanding. Our products are built by market access experts for market access professionals."
Keshav Nagaraja
Managing Director, Access Infinity Digital
"We’re pleased to welcome Access Infinity’s NURO solution to the Microsoft Azure Marketplace, which gives our partners great exposure to cloud customers around the globe. Azure Marketplace offers world-class quality experiences from global trusted partners with solutions tested to work seamlessly with Azure."
Jake Zborowski
General Manager, Microsoft Azure Platform at Microsoft Corp

The Azure Marketplace is an online market for buying and selling cloud solutions certified to run on Azure. The Azure Marketplace helps connect companies seeking innovative, cloud-based solutions with partners who have developed solutions that are ready to use.

About Access Infinity

Founded in 2014, Access Infinity exists to help pharma companies confront their challenges head-on. The company began as a consulting firm to guide pharma businesses in developing and implementing effective market access and pricing strategies. It has since introduced market-redefining digital tools, NURO, Access Hub and Evidence Library to help market access teams work smarter, faster, and more efficiently with valuable insights at their fingertips.
With offices in London, Hyderabad, New York and Manchester, Access Infinity is experiencing rapid growth as it continues to transform and simplify market access for pharmaceutical organizations globally. Clients include GSK, Astra Zeneca, Johnson & Johnson, Pfizer, and Amgen. The business was named a Top 5 Pharma Tech company by Pharma Outlook in 2021 and received the Stevie® Award for Small Company of the Year 2021.
For more information, press only:
Tel: +44 (0)207 078 7643
Join us

Analyst/Senior Analyst (Market Access)

What we can offer:

A leadership team with more than half a century of the highest-level pricing and market access experience means that Access Infinity is a great place to develop your skills in the field as part of our innovative and growing team.

  • We have a strong training and development programme with 20+ learning modules to give you the best start to your global market access career. These include subject matter training in market access and pricing as well as transferable skills such as project management and presentation writing
  • You will learn the best practices in project management from true leaders in the industry, in a friendly and fun environment
  • Support will always be available from the senior team in an accessible, flat company structure
  • Development opportunities and performance/promotion reviews to accelerate your development
  • We believe in rewarding high performance and offer a generous compensation package. 
About you:

We seek experienced candidates having a thorough insights in global pharma pricing, reimbursement, and cost of therapy to fill this position. An understanding of market regulation for pharmaceuticals, indication-based reimbursement, health technology assessment process in major markets is an advantage.

What we are looking for:

  • Key Responsibilities 

    • Market Access and HTA assessments data collection and analysis from different sources and secondary and primary research
    • Understand the NURO platform data and its use cases, to support with client delivery and platform development
    • Work closely with the Data & Analytics team to collect and analyse HTA data as needed and identify avenues for new and improved analytical insights
    • Support with analytics and insights on consulting projects
    • Support the management of data assets via quality checking and testing, and identifying solutions to problems
    • Work with teams across AI to generate analytical content.


  • 2-4 years’ Experience analysing HTA decision-making and outcomes
  • Understanding of different healthcare settings and pricing and reimbursement of medicines in major EU markets, US and Japan
  • Conduct secondary research and work independently to assure correct and relevant information and analysis are provided
  • Manages data collection, processing, quality assurance
  • Detailed oriented, rapid response kind of attitude
  • Excellent in stakeholder communication with strong inter-personal skills. 

Please email your CV and cover letter along to careers.india@accessinfinity.com with the role you are applying for as the subject.


Excel tools for Global Pricing and Market Access teams

Authored by 
Shrinivas Rao Mukku, Ph. D, M. Phil (Cantab), Founding Director, Access Infinity.
Vanit Patel, Senior Consultant, Access Infinity. 


Excel is a powerful tool that is widely used for developing models in various sectors, including our own, the pharmaceutical industry. Within pharma, forecasting teams use it to forecast sales, commercial teams to analyse revenue scenarios and clinical teams to interpret data, on a daily basis. For the pricing and market access function, some excel tools are essential and constantly used to support decision making at different stages of the product life cycle. Several companies, including Access Infinity offer these tools as products and services to the Global Pricing and Market Access function.

Excel tools do their job

Excel has limitations when it comes to user interface and UX design however it does have several advantages such as ease and speed of build, scalability and editing flexibility. It also enables users to see and amend calculations.

During our time as a Market Access and Pricing (MAP) consultancy business, we’ve seen time and time again how clients use Excel to great effect. In this article, we’ve pulled together our top 10 tools that specifically serve the global MAP function.

1. International Price Referencing (IRP) Tool

Excel IRP tools are commonly used by pricing teams to determine the impact of IRP on different countries and the subsequent influence on global price corridors. By analysing and quantifying the negative impact of IRP, these Excel tools can help generate a revenue-optimising country launch sequence. They are also used to mitigate and reduce IRP-driven price erosion as part of a product’s post launch lifecycle management. 

2. Country launch sequencing

Launch sequencing of a product in different countries is one of the key strategic responsibilities of global pricing and market access function. Launch sequencing in many instances is an extension of IRP modelling. In addition to this, the time taken to conduct the HTA review, and the subsequent price negotiation are also incorporated as inputs while developing the optimal launch sequence. This varies by country and could be between 0 – 400 days. Mitigating the risk of IRP impact through optimal launch sequence is achieved by closely monitoring the outcomes of price negotiations factoring what price is visible and the time it is published in the national journal for other countries to access. Launch sequence is closely monitored and global price approval teams need to flexible to make quick tactical decisions. 

3. Parallel trade impact analysis

Parallel trade is one of the key challenges pharmaceutical companies face. It is therefore important to identify the countries that are impacted and assess the implications to revenue. This would help in not only managing the risk through different tactical decisions but also considering other elements of price referencing as well as parallel trade laws. Based on the understanding of which countries are impacted and the magnitude of loss, strategies could be developed to curtail this, e.g. packaging, language on the pack etc.

4. Revenue optimisation

Revenue-optimisation excel tools can cater to many use cases such as the optimisation of revenues based on the line of usage (patient volumes x price potential) or analysing the impact of different pricing scenarios. As the name suggests, these Excel models can include multiple variables to assess short- and long-term revenues to inform strategic decisions.  Revenue optimisation tools are typically used at every stage of the product lifecycle.

5. Indication sequencing

Indication sequencing tools are important for analysing the overall revenue for a product launching in multiple indications. This is extremely common in oncology and immunology where products are often tested in various distinct indications and lines of treatments. Price potential and volumes can vary by indication and are driven by the price and LOE (loss of exclusivity) status of competitor products, along with the incidence and prevalence of the diseases.

Modelling indication sequencing can help guide the cross-indication launch strategy and is critical not only for the P&MA function but also to influence R&D and commercial planning.

6. Risk sharing agreements

Many payer institutions are looking at managed entry agreements to make novel, expensive products, more accessible. Managed entry agreements exist in multiple options such as pure-play discounting, free goods, cumulative tiered pricing, pay for performance and others. The revenue analysis based on these options can also evaluate launching in multiple indications and multiple countries.  

An excel tool that is able to intuitively compare the revenues of all the options for both the pharmaceutical account managers as well as payers to make access decisions, is a win-win for both parties. Our experience indicates that simple calculators for account managers can help in quick decision making as one is able to present which agreement serves the purpose of the payer, both at the regional and/or hospital level. 

7. Price calculator

The margins applied on the ex-factory price to arrive at the price paid by the consumer (list price) and other stakeholders vary by market. Margins are applied at the wholesaler level and pharmacy level and the percentages in any country depends on several factors such as the point of care, distribution channel (hospital vs retail) and cost of the medicine. For instance, for more expensive products, the percentage commission is lower for both wholesalers and pharmacies.

Another variable is the addition of government tax e.g. VAT (value added tax), GST (goods and services tax) and others. This also varies if the product is funded through the retail route or hospital. The most complex price to estimate is the net price which is based on the discounts applied at ex-factory, wholesaler or pharmacy levels.

Price calculators are simple Excel tools that can help derive prices at all levels for a given product in each country. Users are able to select a country, input one of the known prices (list, ex-factory, pharmacy or wholesaler price)  and the tool is able to determine automatically prices at all other levels for that country.

8. Due Diligence framework

Due diligence of potential acquisitions is conducted on a frequent basis and is a time drain for many P&MA executives. To ensure that a systematic approach is used for due diligence exercises, a simple model can help to assess product value at the time of its launch.  

This framework helps in defining the product environment through scoring of disease severity, unmet need, current and future competition, patient numbers and prices of current treatments. Once the environment is defined, users can overlay the product characteristics being tested, including the efficacy and safety of the product over its current and future competition and the quality of data supporting it. Through a simple logic of value differentiation, one can derive the potential HTA outcome and price of the product. Although the hypotheses is based on performance of past launches and future competition, it is a great starting point to conduct a quick BD assessment. 

9. Price forecasting tool

Pricing teams play a key role in product investment decisions – they need to generate defendable price forecasts to assess if assets are worth investing in. 

An Excel model can help to forecast the price in several countries and/or regions. Country-specific baseline assumptions can be used to estimate price evolution over time. Example assumptions include: time to reimbursement, gross-to-net discount, LOE and price changes due to specific country events such as mandatory price cuts, currency conversion policy and others. This provides a quick and validated starting point for users to tailor their forecast.

10. Payer decision driver matrix

As payer expectations, reimbursement drivers and WTP vary across markets, tools that map where an asset is meeting expectations can be of great use. In order to effectively plan evidence-generation activities, teams must be able to identify, categorize and track payer expectations and the associated data gaps.

An Excel tool provides the ability to collate this information as a single source of truth that enables teams to:

  • Understand country-specific payer decision drivers
  • Track and make informed decisions on the evidence generation activities to pursue
  • Easily share and distribute information with internal teams

Let us know your top Excel tools

In this article we’ve shared our top 10 Excel tools for Market Access and Pricing teams, based on our experiences in industry and client feedback. 

How many of these tools are you using in your own team? Are there any others that you think should make our list? 

We’d love to hear your thoughts, drop us a line on hello@access-infinity.com.

About the authors

Dr. Shrinivas Rao Mukku (Shri)

Shri is the founding director of Access Infinity and has 16+ years of consulting and industry experience. Shri worked at Merck as Global Director, MAP (Market Access and Pricing) responsible for Erbitux and other oncology products and at Lundbeck as ‘Pricing Specialist’ in the Global Pricing team. Work in many regions and countries including UK, the current location, France, Germany, Denmark and Southeast Asia in biotech, pharma, research and management consulting has led to a very good understanding of drivers of access globally. In addition, this has led to personally managed of strong network of payers and key opinion leaders.

Shri’s consulting experience includes launch pricing strategy, country and indication sequencing, qualitative payer and KOL research on impact of clinical evidence generation on product value assessment, post LoE (loss of exclusivity) pricing strategy and assessment of new products for BD opportunities (in- and out-licensing). He has also established and/or led pricing and market access departments of different consulting companies such as Access Partnership and Double Helix Consulting. With is strong interest in excel tools, he has developed several on-demand tools for pharma clients. Shri has a Ph.D in Bioprocess Engineering from Asian Institute of Technology, Bangkok and an M.Phil from the University of Cambridge, UK in Bioscience Enterprise as a fellow of Melinda and Gates foundation.

Vanit Patel

Vanit is a senior consultant at Access Infinity and has 6+ years consulting in the healthcare industry. In this time, he has created 20+ bespoke Excel models for top-20 pharmaceutical companies. Vanit has also conducted and managed over 60 projects focusing on global pricing and market access strategy, evidence generation, value assessment, value message creation and testing, international reference pricing, forecasting, due diligence exercises and leading internal client workshops.

Vanit is a UK qualified pharmacist, graduating from University College London (UCL). He previously worked at the Royal Free London NHS foundation trust and also completed academic research at Monash University in Australia, where he studied PfPDE inhibition and produced published data on PI3K inhibition.